A Review of the Role of FEV₁ in the COPD Paradigm

REFERENCES

• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2006 Executive Summary, Available from: www.goldcopd.com [cited 2007 May 16]
   Google Scholar
• Celli B R, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–946
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Surveillance Summaries. U.S. Department of Health and Human Services. 2002
   Google Scholar
• Centers for Disease Control and Prevention. Surveillance Summaries. U.S. Department of Health and Human Services. 2002
   Google Scholar
• Mannino D, Homa D, Akinbami L, Ford E, Redd S. Chronic Obstructive Pulmonary Disease Surveillance—United States, 1971–2000. Morb Mortal Wkly Rep 2002; 51: 1–16
   Google Scholar
• Miller M R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten C P, Gustafsson P, Jensen R, Johnson D C, MacIntyre N, McKay R, Navajas D, Pedersen O F, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. Eur Respir J 2005; 26: 319–338
   PubMed Web of Science ®Google Scholar
• Ferguson G T, Enright P L, Buist A S, Higgins M W. Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. Chest 2000; 117: 1146–1161
   PubMed Web of Science ®Google Scholar
• Hankinson J, Odencrantz J, Fedan K. Spirometric Reference Values from a Sample of the General U. S. Population. Am Rev Resp Crit Care Med 1999; 159: 179–187
   PubMed Web of Science ®Google Scholar
• Hutchinson J. Med Chir Tr 1846; 29: 137
   PubMedGoogle Scholar
• Gaensler E A. Analysis of the ventilatory defect by timed capacity measurements. Am Rev Tuberc 1951; 64: 256–278
   PubMedGoogle Scholar
• Kannel W B, Lew E A, Hubert H B, Castelli W P. The value of measuring vital capacity for prognostic purposes. Trans Assoc Life Insur Med Dir Am 1980; 64: 66–83
   PubMedGoogle Scholar
• Petty T L, Doherty D E. The National Lung Health Education Program: roots, mission, future directions. Respir Care 2004; 49: 678–683
   PubMedGoogle Scholar
• Who we are. 2007, Available from: http://www.nlhep.org/who.html [cited 2007 June 7, 2007]
   Google Scholar
• Hansen J E, Sun X G, Wasserman K. Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not < 70%. Chest 2007; 131: 349–355
   PubMed Web of Science ®Google Scholar
• Fulambarker A, Copur A S, Javeri A, Jere S, Cohen M E. Reference values for pulmonary function in Asian Indians living in the United States. Chest 2004; 126: 1225–1233
   PubMed Web of Science ®Google Scholar
• Ferguson G T. Why does the lung hyperinflate?. Proc Am Thorac Soc 2006; 3: 176–179
   PubMedGoogle Scholar
• NCQA. NCQA Releases HEDIS®. 2006, Available from: http://www.ncqa.org/communications/news/hedis_2006.htm New measures address overuse, follow-up. [cited 2007 May 16]
   Google Scholar
• Doherty D E. The pathophysiology of airway dysfunction. Am J Med 2004; 117(Suppl 12A)11S–23S
   PubMedGoogle Scholar
• Barnes P J. Mechanisms in COPD: differences from asthma. Chest 2000; 117: 10S–14S
   PubMed Web of Science ®Google Scholar
• Burrows B. Airways obstructive diseases: pathogenetic mechanisms and natural histories of the disorders. Med Clin North Am 1990; 74: 547–559
   PubMed Web of Science ®Google Scholar
• Hodgkin J E. Prognosis in chronic obstructive pulmonary disease. Clin Chest Med 1990; 11: 555–569
   PubMed Web of Science ®Google Scholar
• Traver G A, Cline M G, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up study. Am Rev Respir Dis 1979; 119: 895–902
   PubMed Web of Science ®Google Scholar
• Pauwels R A, Buist A S, Calverley P M, Jenkins C R, Hurd S S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256–1276
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Executive Summary: Global Strategy for the Diagnosis, Management, and Prevention of COPD. 2006, Available from: http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=996[cited 2007 May 5, 2007]
   Google Scholar
• O'Donnell D E, Lam M, Webb K A. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 542–549
   PubMed Web of Science ®Google Scholar
• Van d en, Eeden S K, Friedman G D. Forced expiratory volume (1 second) and lung cancer incidence and mortality. Epidemiology 1992; 3: 253–257
   PubMed Web of Science ®Google Scholar
• Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J 2003; 21: 1012–1016
   PubMed Web of Science ®Google Scholar
• Wannamethee S G, Shaper A G, Ebrahim S. Respiratory function and risk of stroke. Stroke 1995; 26: 2004–2010
   PubMed Web of Science ®Google Scholar
• Mannino D M, Holguin F, Pavlin B I, Ferdinands J M. Risk factors for prevalence of and mortality related to restriction on spirometry: findings from the First National Health and Nutrition Examination Survey and follow-up. Int J Tuberc Lung Dis 2005; 9: 613–621
   PubMed Web of Science ®Google Scholar
• Ferrer M, Alonso J, Morera J, Marrades R M, Khalaf A, Aguar M C, Plaza V, Prieto L, Anto J M. Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med 1997; 127: 1072–1079
   PubMed Web of Science ®Google Scholar
• Friedman M, Serby C W, Menjoge S S, Wilson J D, Hilleman D E, Witek T J, Jr. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115: 635–641
   PubMed Web of Science ®Google Scholar
• Burge P S, Calverley P M, Jones P W, Spencer S, Anderson J A, Maslen T K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Bmj 2000; 320: 1297–1303
   PubMed Web of Science ®Google Scholar
• Dewan N A, Rafique S, Kanwar B, Satpathy H, Ryschon K, Tillotson G S, Niederman M S. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 2000; 117: 662–671
   PubMed Web of Science ®Google Scholar
• Anthonisen N R, Connett J E, Murray R P. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675–679
   PubMed Web of Science ®Google Scholar
• Pfizer I. EXUBERA® Prescribing Information. New York 2007
   Google Scholar
• Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645–1648
   PubMed Web of Science ®Google Scholar
• Camilli A E, Burrows B, Knudson R J, Lyle S K, Lebowitz M D. Longitudinal changes in forced expiratory volume in one second in adults. Effects of smoking and smoking cessation. Am Rev Respir Dis 1987; 135: 794–799
   PubMed Web of Science ®Google Scholar
• Lange P, Groth S, Nyboe G J, Mortensen J, Appleyard M, Jensen G, Schnohr P. Effects of smoking and changes in smoking habits on the decline of FEV1. Eur Respir J 1989; 2: 811–816
   PubMed Web of Science ®Google Scholar
• Peat J K, Woolcock A J, Cullen K. Decline of lung function and development of chronic airflow limitation: a longitudinal study of non-smokers and smokers in Busselton, Western Australia. Thorax 1990; 45: 32–37
   PubMed Web of Science ®Google Scholar
• Wilhelmsen L, Orha I, Tibblin G. Decrease in ventilatory capacity between ages of 50 and 54 in representative sample of Swedish men. Br Med J 1969; 3: 553–556
   PubMed Web of Science ®Google Scholar
• Xu X, Dockery D W, Ware J H, Speizer F E, Ferris B G, Jr. Effects of cigarette smoking on rate of loss of pulmonary function in adults: a longitudinal assessment. Am Rev Respir Dis 1992; 146: 1345–1348
   PubMed Web of Science ®Google Scholar
• Gorecka D, Bednarek M, Nowinski A, Puscinska E, Goljan-Geremek A, Zielinski J. Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest 2003; 123: 1916–1923
   PubMed Web of Science ®Google Scholar
• Hepper N G, Drage C W, Davies S F, Rupp W M, LaMothe J, Schoenfelder P G, Munson P. Chronic obstructive pulmonary disease: a community-oriented program including professional education and screening by a voluntary health agency. Am Rev Respir Dis 1980; 121: 97–104
   PubMed Web of Science ®Google Scholar
• Petty T L, Pierson D J, Dick N P, Hudson L D, Walker S H. Follow-up evaluation of a prevalence study for chronic bronchitis and chronic airway obstruction. Am Rev Respir Dis 1976; 114: 881–890
   PubMed Web of Science ®Google Scholar
• Zielinski J, Bednarek M. Early detection of COPD in a high-risk population using spirometric screening. Chest 2001; 119: 731–736
   PubMed Web of Science ®Google Scholar
• Bednarek M, Gorecka D, Wielgomas J, Czajkowska-Malinowska M, Regula J, Mieszko-Filipczyk G, Jasionowicz M, Bijata-Bronisz R, Lempicka-Jastrzebska M, Czajkowski M, Przybylski G, Zielinski J. Smokers with airway obstruction are more likely to quit smoking. Thorax 2006; 61: 869–873
   PubMed Web of Science ®Google Scholar
• Buffels J, Degryse J, Decramer M, Heyrman J. Spirometry and smoking cessation advice in general practice: a randomised clinical trial. Respir Med 2006; 100: 2012–2017
   PubMed Web of Science ®Google Scholar
• Casanova C, Cote C, de Torres J P, Aguirre-Jaime A, Marin J M, Pinto-Plata V, Celli B R. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 591–597
   PubMed Web of Science ®Google Scholar
• Celli B R, Cote C G, Marin J M, Casanova C, Montes de Oca M, Mendez R A, Pinto Plata V, Cabral H J. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005–1012
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler D A, Jones P W, Wanner A, San P G, ZuWallack R L, Menjoge S S, Serby C W, Witek T, Jr. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217–224
   PubMed Web of Science ®Google Scholar
• Vincken W, van Noord J A, Greefhorst A P, Bantje T A, Kesten S, Korducki L, Cornelissen P J. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19: 209–216
   PubMed Web of Science ®Google Scholar
• Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 2004; 24: 206–210
   PubMed Web of Science ®Google Scholar
• Calverley P M, Anderson J A, Celli B, Ferguson G T, Jenkins C, Jones P W, Yates J C, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789
   PubMed Web of Science ®Google Scholar
• Decramer M, Celli B, Tashkin D P, Pauwels R A, Burkhart D, Cassino C, Kesten S. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. Copd 2004; 1: 303–312
   PubMedGoogle Scholar
• Canadian Lung Association. Chronic obstructive pulmonary disease (COPD): A national report card. Canadian Lung Association and the Canadian Thoracic Society. 2005
   Google Scholar